Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
158 hedge funds and large institutions have $328M invested in Clovis Oncology, Inc. in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 60 increasing their positions, 38 reducing their positions, and 30 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 38
46% more capital invested
Capital invested by funds: $224M → $328M (+$103M)
34% more call options, than puts
Call options by funds: $31.8M | Put options by funds: $23.7M
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
3% more funds holding
Funds holding: 154 → 158 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$42.2M |
| 2 |
BlackRock
New York
|
+$13.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 4 |
AC
Armistice Capital
New York
|
+$12.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$8.88M |
| 2 |
AG
Artal Group
Luxembourg
|
-$7.57M |
| 3 |
SG Americas Securities
New York
|
-$3.01M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.01M |
| 5 |
CAC
Cowen and Company
New York
|
-$2.96M |
CLVS Hedge Fund Activity: Q2 2020 in Review
158 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2020, worth a combined $328M — up 46% from $224M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CLVS positions and 30 closed out — a net gain of 5 holders — while 60 added to existing stakes and 38 trimmed.
The largest buyer was State Street, adding an estimated $42.2M. The largest seller was Goldman Sachs, cutting an estimated $8.88M.
- 158 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2020, up from 154 in Q1 2020.
- Funds reported $328M of Clovis Oncology, Inc. stock for Q2 2020, up 46% quarter-over-quarter.
- 35 funds opened new Clovis Oncology, Inc. positions in Q2 2020 and 30 closed out, a net change of +5 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2020 was State Street, an estimated $42.2M added.
- The largest Clovis Oncology, Inc. seller in Q2 2020 was Goldman Sachs, an estimated $8.88M sold.
Based on aggregated 13F filings for Q2 2020.